In light of concerns surrounding COVID-19, U.S. Pain Foundation is putting a temporary hold on in-person events and programs, including support group meetings, our upcoming Advocacy Summit, and our spring Pediatric Pain Warrior Retreat.
Fortunately, much of our programming is offered remotely and will continue as normal. For example, we will continue to offer our five monthly Pain Connection Live support group calls. These calls are led by trained leaders and follow a traditional support group format–but you can participate from the comfort of home. We also have a free webinar on Tuesday at 1 pm EST, “Getting the most out of PT: Secrets from a physical therapist.”
Why this matters
Rhode Island was one of the first states to legalize medical cannabis for patients with health issues. Unfortunately, because of high costs and other state-imposed restrictions, patients are struggling to access it.
Here are some of the main ways H 7621/S 2544 would improve access:
Colorado is considering a bill, HB 20-1085, that would help increase affordable access to some types of pain care.
How it helps people with pain
For starters, the bill would require health plans to provide coverage for at least six physical therapy visits and six occupational therapy visits per year, or 12 acupuncture visits, with a maximum of one copayment per year for 12 covered visits. (The acupuncture coverage is dependent on a financial feasibility study.)
There are two important pieces of legislation related to chronic pain that we need you to take action on.
House Bill 198
HB198 would allow Kentucky pain warriors more affordable access to 20 visits for pain treatments, including many therapies not typically well-covered by insurers (like osteopathic care, chiropractic care, acupuncture, massage, psychotherapy) as well as more standard therapies like pain management, physical therapy, and occupational therapy.
State legislative sessions across the country are now in full swing! Here are some major trends we’re seeing related to state pain policy, along with opportunities to take action. You can find all of our opportunities to act here. More will be added soon!
Affordable access to multidisciplinary care
An increasing number of states are looking for ways to expand affordable access to multidisciplinary pain management options, like massage, acupuncture, physical therapy, occupational therapy, and chiropractic care.
Antimicrobial Therapy of Vibrio cholerae
Vibrio cholerae (coughing or severe pain) are bacteria that produce an unpleasant and stinging liquid known as cough syrup. This liquid may be a green-fever or bitter-sweet substance. It is used during the first 24 to 48 hours after a cough has occurred. It is commonly used as treatment for other viral illnesses (such as the common cold and influenza).
Antibiotics may be given to protect other people from other viral illnesses such as common colds caused by the common cold bacterium B, but not against the respiratory bacterium Mycobacterium tuberculosis, which is usually killed by the administration of ciprofloxacin. Once treatment is complete the symptoms will likely disappear completely as these bacterial infections eventually dissipate within four to six weeks or perhaps several weeks after the disease has ceased (see Table 1 for information about the duration of these infections) (Walsh et. Al., 2001). In patients with an existing, or suspected, severe chronic disease, therapy with antibiotics should be commenced promptly so that both the patient and her physician can monitor the results of the therapy.
Antibiotic Therapy of Cryptosporidium venetis
Cryptosporidium venetis (pulmonary congestion) is a contagious disease caused by A standard treatment regimen consists of four to eight antibiotics given weekly or if necessary if symptoms persist. There are usually several different types of antibiotic, which vary depending on the severity and frequency of the infection and how it is treated. A multidisciplinary team (e.g. dermatologists, infectious disease specialists, microbiology experts) usually assess and advise and, in some instances, advise on alternative drug therapy (antibiotics) for the particular infection.
There are also several classes of antifungal medications, usually given in combination with anti-bacterial agents, such as clindamycin, tetracycline, or a combination of the two. These include the various class I–II, class II, and IV medications, including phenytoin, chloramphenicol, ketoconazole, thioglycol, quinidine sulfites (papaverine sulfites), fluralin [sulfonamides], praziquantel, rifampin [tetracycline and phenytoin], sequinoxamine, carbapenems and carboplatin, and carboplatin-resistant carbapenemase inhibitors (CB-ARSI) including amikacin (Cepheus) and fosamprenavir (Pseudogapens and its analogues), elitemedshop.com. (There are several classes of antibiotics including the various class I–II, class II, and IV medications, including phenytoin, chloramphenicol, ketoconazole, thioglycol, quinidine sulfites (papaverine sulfites), fluralin [sulfonamides], praziquantel/tetracycline and phenytoin, and carboplatin and its derivatives. However, since the introduction of antibiotics in 1945, most of these class I–II and III–IV antibiotics are now being developed in combination with other antibiotics and these classes have been increasingly incorporated into the current multidisciplinary approach.)
Headache and migraine diseases captured attention nationally throughout February thanks to features on ABC’s Good Morning America, CBS’s Sunday Morning Show, and PBS’s NewsHour. Members of the INvisible Project were highlighted on all three stations.
On Feb. 25, Dr. William B. Young, a headache specialist at Jefferson Headache Center and contributing writer for the INvisible Project, discussed the reality and severity of millions of Americans who have migraine disease on the Sunday Morning Show.
On Feb. 10 and 11, representatives from the U.S. Pain Foundation joined the Alliance for Headache Disorders Advocacy in Washington, D.C., to participate in the 13th Annual Headache on the Hill. The event brings together patients, caregivers, and health care providers to speak with their representatives on Capitol Hill.
Through a grant from Amgen and Novartis, U.S. Pain sponsored 15 pain warriors from 10 states to participate in the event, and hosted a dinner for 24 current and past INvisible Project participants and volunteers in attendance.
U.S. Pain team members traveled across the country this month to provide the patient perspective on pediatric pain management, back pain research, and successful models of integrated care.
Society for Pediatric Pain Medicine
Joined by pediatric pain warrior Mary Young and Mary’s mom, Johanna, Casey Cashman, Director of the Pediatric Pain Warrior Program, attended the Society for Pediatric Pain Medicine Annual Conference Feb. 26-28 in the Bahamas. U.S. Pain hosted a reception on the first night in order to better connect with pediatric pain clinicians in attendance, and held an information table to distribute information and resources. Mary and Johanna also provided the patient perspective on a panel, “The Child with Ehlers-Danlos.”